Physician profile
Sanjeev Bhatta
NPI 1770576100
$2,366.90
in general payments reported to CMS, 2019-2025
26 companies · $309 in 2025
The $309 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $364 · 2020: $451 · 2021: $375 · 2022: $494 · 2023: $210 · 2024: $164 · 2025: $309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $242.32 | 2020-2025 | Lifevest |
| Medtronic, INC. | $214.28 | 2021-2025 | Cobalt Dr Mri Surescan, Linq II |
| Janssen Pharmaceuticals, INC | $191.89 | 2019-2024 | Xarelto, Spravato |
| Merck Sharp & Dohme LLC | $181.63 | 2022-2023 | Verquvo |
| Boston Scientific Corporation | $177.17 | 2019-2025 | Resonate El Icd Vr, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $172.84 | 2020-2024 | |
| Neuronetics, INC. | $155.94 | 2019-2025 | Neurostar Tms Therapy System |
| Amgen INC. | $151.18 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $149.95 | 2019-2025 | |
| Cardiovascular Systems INC. | $119.86 | 2019-2021 | |
| Venclose INC. | $81.50 | 2020 | |
| Shockwave Medical, INC | $73.06 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $71.63 | 2020-2025 | Eliquis |
| Medtronic Vascular, INC. | $64.34 | 2019-2020 | |
| Novo Nordisk INC | $52.17 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $47.16 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $33.12 | 2021-2025 | Rotarexs 6 F X 135 Cm |
| Esperion Therapeutics, INC. | $32.14 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $25.42 | 2024 | Ingrezza |
| Edwards Lifesciences Corporation | $22.96 | 2019 | |
| Abbott Laboratories | $21.58 | 2022 | |
| Brainsway USA INC | $20.76 | 2019 | |
| Livanova USA, INC. | $19.98 | 2021 | |
| Inspire Medical Systems, INC. | $17.89 | 2024 | Inspire |
| Penumbra, INC. | $16.13 | 2025 | Penumbra System |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeev Bhatta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.